Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
Adjuvant therapy with durvalumab led to significantly longer overall survival and progression-free survival than placebo among patients with limited-stage small-cell lung cancer. (Funded by AstraZeneca; ADRIATIC ClinicalTrials.gov number, NCT03703297.).
Authors
- Yoshimasa Shiraishi (ORCID: https://orcid.org/0000-0001-5015-193X)
- Ki Hyeong Lee (ORCID: https://orcid.org/0000-0002-7830-5950)
- David R. Spigel (ORCID: https://orcid.org/0000-0003-3215-9465)
- Qiming Wang (ORCID: https://orcid.org/0000-0002-7813-2885)
- Hema Gowda (ORCID: https://orcid.org/0009-0002-2069-8891)
- Alejandro Navarro (ORCID: https://orcid.org/0000-0001-5903-270X)
- Sema Sezgin Göksu (ORCID: https://orcid.org/0000-0002-8026-764X)
- Haiyi Jiang (ORCID: https://orcid.org/0009-0002-8677-6821)
- Yuanbin Chen (ORCID: https://orcid.org/0009-0006-4175-8055)
- Byoung Chul Cho (ORCID: https://orcid.org/0000-0002-5562-270X)
- Davey B. Daniel (ORCID: https://orcid.org/0000-0001-9647-0119)
- A. Badzio
- Reyes Bernabé (ORCID: https://orcid.org/0000-0003-0312-9195)
- Helen Mann
- Yoshitaka Zenke (ORCID: https://orcid.org/0000-0002-7641-9065)
- Jian Fang (ORCID: https://orcid.org/0000-0002-1077-3686)
- К. К. Лактионов (ORCID: https://orcid.org/0000-0003-4469-502X)
- Nguyễn Thị Thái Hòa (ORCID: https://orcid.org/0000-0002-9979-2241)
- Milada Zemanová (ORCID: https://orcid.org/0000-0002-1904-1035)
- John Wen-Cheng Chang
- E.L. Buchmeier
- Suresh Senan
- Ying Cheng (ORCID: https://orcid.org/0009-0008-8384-2647)
- Anhui Shi
Institutions
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1056/nejmoa2404873
- Citations
- 228
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 64.14
Funders
- AstraZeneca